PILL:NYE-Direxion Daily Pharmaceutical & Medical Bull 3X Shares ETF (USD)

ETF | Trading--Leveraged Equity |

Last Closing

USD 9.3

Change

+0.13 (+1.42)%

Market Cap

N/A

Volume

6.30K

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-10-29 )

Largest Industry Peers for Trading--Leveraged Equity

Symbol Name Price(Change) Market Cap
SOXL Direxion Daily Semiconductor B..

+2.63 (+7.44%)

USD 11.35B
QLD ProShares Ultra QQQ

+1.95 (+1.89%)

USD 7.34B
FNGU MicroSectors FANG+ Index 3X Le..

+21.93 (+4.88%)

USD 5.84B
SSO ProShares Ultra S&P500

+0.28 (+0.30%)

USD 5.40B
UPRO ProShares UltraPro S&P500

+0.38 (+0.43%)

USD 4.05B
TECL Direxion Daily Technology Bull..

+3.62 (+3.96%)

USD 3.44B
YINN Direxion Daily FTSE China Bull..

-0.69 (-1.95%)

USD 2.18B
USD ProShares Ultra Semiconductors

+4.51 (+3.28%)

USD 1.31B
LABU Direxion Daily S&P Biotech Bul..

-0.13 (-0.10%)

USD 0.91B
DPST Direxion Daily Regional Banks ..

-2.41 (-2.13%)

USD 0.74B

ETFs Containing PILL

N/A

Market Performance

  Market Performance vs. Industry/Classification (Trading--Leveraged Equity) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 1,700.00% 94% A 98% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 1,700.00% 94% A 98% N/A
Trailing 12 Months  
Capital Gain 2,619.30% 94% A 98% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 2,619.30% 94% A 98% N/A
Trailing 5 Years  
Capital Gain 794.69% 91% A- 96% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 794.69% 91% A- 96% N/A
Average Annual (5 Year Horizon)  
Capital Gain 28.30% 61% D- 87% B+
Dividend Return 28.79% 60% D- 86% B+
Total Return 0.49% 38% F 12% F
Risk Return Profile  
Volatility (Standard Deviation) 282.69% 15% F 3% F
Risk Adjusted Return 10.19% 21% F 29% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.